Potential Role of MicroRNA-210 as Biomarker in Human Cancers Detection: A Meta-Analysis

Table 1

Characteristics of the included studies.

First author	Year	Country	Ethnicity	Sample size		Male		Cancer	Specimen	Diagnostic power				QUADAS
				Control	Case	Control	Case			TP	FP	FN	TN
Wang [16]	2009	USA	Caucasian	44	34	0.51	n.a.	Pancreatic cancer	Plasma	18	9	26	25	4
Xing [17]	2010	USA	Caucasian/African	48	48	0.68	0.54	Lung cancer	Sputum	28	10	20	38	5
Shen [18]	2011	USA	Caucasian/African	76	80	0.55	0.63	Lung cancer	Plasma	43	22	33	58	5
Shen [26]	2011	USA	Caucasian/African	58	29	0.68	0.66	Lung cancer	Plasma	46	7	12	22	6
Madhavan [32]	2012	Germany	Caucasian	61	76	n.a.	n.a.	Breast cancer	Plasma	51	14	10	62	7
				72	76	n.a.	n.a.	Breast cancer	Plasma	45	37	27	39
Ren [33]	2012	China	Asian	29	13	0.66	0.62	Pancreatic cancer	Fecal	25	4	4	9	6
Xie [27]	2012	China	Asian	45	30	0.62	0.57	Leukemia	Serum	41	6	4	24	4
Anjuman [28]	2013	USA	Caucasian/African	39	42	0.59	0.61	Lung cancer	Sputum	27	10	12	32	5
Zhao [34]	2013	France	Caucasian	68	42	0.68	0.52	Renal cancer	Serum	55	9	13	33	6
Iwamoto [5]	2014	Japan	Asian	34	23	0.76	0.48	Renal cancer	Serum	22	4	12	19	4
Li [35]	2014	USA	Caucasian/African	35	40	0.63	0.65	Lung cancer	Sputum	20	4	15	36	6
Shen [36]	2014	USA	Caucasian/African	64	73	0.64	0.66	Lung cancer	Sputum	43	18	23	50	5

n.a.: not available; TP: true positive; FP: false positive; FN: false negative; TN: true negative; QUADAS: quality assessment of diagnostic accuracy studies.